Less than a tenth of patients who could benefit from weight-loss injections including Wegovy have access to them, states the WHO as it issues its inaugural guidance on the medications.
Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just access to these injectable treatments.
Per estimates, more than two billion could be obese by 2030 without intervention.
"The new guidelines recognises that obesity is a long-term condition that can be managed with thorough and lifelong care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major barriers to universal access to the treatments that can help people shift considerable weight, notes the body.
Skinny Jab Scarcity
Despite the current best projected case, the supply of these medications would only suffice for around 100 million people – under 10% of the global need, according to the WHO.
The recommendation encourages countries and companies to widen access, via approaches including voluntary licensing.
A patent on a key compound – the main ingredient of a leading brand – is set to lapse in multiple countries in 2026.
How Obesity Drugs Operate
The injections mimick a natural hormone to slow digestion, reduce hunger and increase feelings of fullness so individuals consume fewer calories.
Individuals usually begin shedding pounds after several weeks of commencing the weekly injections.
Evidence suggests patients may put most of the weight back on after a year of discontinuing the drug, because their typical appetite come back.
Being overweight or obese elevates your chance for contracting health problems, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight concerns individuals in every country and was linked to millions of deaths worldwide in 2024, per the health agency.
